Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
- Takeda Set to Bring Entyvio Back to Double-Digit Growth in FY2023: Exec
July 28, 2023
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Pfizer Seeks Pediatric ALL Nod for Besponsa in Japan
July 28, 2023
- AbbVie’s Parkinson’s Drug Vyalev Now Available in Japan
July 27, 2023
- Ono Settles I/O Patent Row with AstraZeneca, Wins US$140 Million
July 26, 2023
- Otsuka Ups H1 Earnings Guidance on Bullish Global Products
July 26, 2023
- Astellas, PeptiDream to Pair Up to Discover Novel Protein Degraders
July 26, 2023
- Trodelvy Launch on Horizon, Gilead Japan to Hire Oncology Reps from Early 2024
July 26, 2023
- After CAR-T Transfer, Gilead Sets Cell Therapy as Key Biz Pillar for Growth in Japan
July 26, 2023
- Kyowa Kirin Seeks Autologous Indication for G-Lasta in Japan
July 25, 2023
- Pfizer’s Aplastic Anemia Med Atgam Now Available in Japan
July 25, 2023
- Tarlige Tops GP Promotion in May, Dayvigo Most Pitched for HP: Intage
July 24, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
- Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
- Lecanemab Shows Large Effect in Low-Tau Population: Clarity AD
July 21, 2023
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- Japan Approves Roche’s Mpox Diagnostic
July 20, 2023
- Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…